BIOLASE, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-12-07: Form 8-K; Period of report 2016-12-07; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2016-11-23: Form 8-K; Period of report 2016-11-22; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2016-11-08: Form 8-K; Period of report 2016-11-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-10-06: Form 8-K; Period of report 2016-09-30; Description 3.02 Unregistered Sales of Equity Securities; 5.07 Submission of Matters to a Vote of Security Holders; Details 3.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-12-07 | 8-K | 2016-12-07 | 7.01 Regulation FD Disclosure | 7.01 Biolase, Inc. will present at the LD Micro Main Event investor conference at the Luxe Sunset Boulevard Hotel in Los Angeles, California on December 7, 2016 and December 8, 2016. | biol-8k_20161207.htm |
| 2016-11-23 | 8-K | 2016-11-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 8, 2016, BIOLASE, Inc. (the "Company") granted Harold C. Flynn, Jr., President and Chief Executive Officer and a director of the Company, a restricted stock unit award representing the right to acquire 1,000,000 shares of Company common stock pursuant to the terms of the BIOLASE, Inc. 2002 Stock Incentive Plan, as amended (the "Plan"), subject to the achievement of specified performance criteria and Mr. Flynn’s continued service with the Company through the applicable vesting dates. | htm_54307.htm |
| 2016-11-08 | 8-K | 2016-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2016, BIOLASE, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2016. | biol-8k_20161108.htm |
| 2016-10-06 | 8-K | 2016-09-30 | 3.02 Unregistered Sales of Equity Securities; 5.07 Submission of Matters to a Vote of Security Holders | 3.02 As previously disclosed, on August 8, 2016, Biolase, Inc. (the "Company") completed its private placement of an aggregate of 88,494 shares of its Series C Participating Convertible Preferred Stock, par value $0.001 per share, (the "Convertible Preferred Stock") and certain warrants (the "Warrants") to purchase up to an aggregate of 2,035,398 shares of the Company’s common stock, par value $0.001 per share (the "Common Stock"). 5.07 On September 30, 2016, a Special Meeting of Stockholders was held at the Company’s headquarters, 4 Cromwell, Irvine, California. | htm_54101.htm |
| 2016-08-08 | 8-K | 2016-08-08 | 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 3.02 On August 8, 2016, Biolase, Inc. (the “Company”) completed its previously announced private placement (the “Private Placement”) of an aggregate of 88,494 shares of its Series C Participating Convertible Preferred Stock, par value $0.001 per share (“Preferred Stock”), and warrants (the “Warrants” and, together with the Preferred Stock, the “Securities”) to purchase up to an aggregate of 2,035,398 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at a price of $2.00 per share, subject to customary anti-dilution adjustments. 3.03 Information concerning the terms, rights, obligations and preferences of the Preferred Stock set forth under Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference. 5.03 On August 8, 2016, the Company filed the Certificate of Designations, Preferences and Rights of Series C Participating Convertible Preferred Stock of Biolase, Inc. (the “Certificate of Designations”) with the Secretary of State of the State of Delaware to establish the terms, rights, obligations and preferences of the Preferred Stock. | d208039d8k.htm |
| 2016-08-02 | 8-K | 2016-08-01 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. | d205227d8k.htm |
| 2016-08-01 | 8-K | 2016-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2016, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2016. | htm_53882.htm |
| 2016-06-08 | 8-K | 2016-06-08 | 7.01 Regulation FD Disclosure | 7.01 On June 8, 2016, David C. Dreyer, Chief Financial Officer of Biolase, Inc. (the “Company”), delivered a presentation at the LD Micro Invitational conference in Los Angeles, California that included a written communication comprised of slides. | d184648d8k.htm |
| 2016-05-12 | 8-K | 2016-05-06 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 6, 2016, the 2016 Annual Meeting of Stockholders of Biolase, Inc. (the "Company") was held at the Company's headquarters, 4 Cromwell, Irvine, California. | htm_53510.htm |
| 2016-05-09 | 8-K | 2016-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2016, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2016. | htm_53480.htm |
| 2016-03-09 | 8-K | 2016-03-09 | 2.02 Results of Operations and Financial Condition | 2.02 On March 9, 2016, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2015. | htm_53230.htm |